WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the expansion of its Fecal Dx™ antigen testing platform with taeniid tapeworm, including Taenia and Echinococcus species. Proven to detect up to twice as many intestinal parasite infections earlier than fecal flotation alone,1 Fecal Dx antigen testing delivers broader parasite detection in a single test for both wellness and sick-pet care. “This advancement re

Combining a potential best-in-class tissue factor-targeting ADC with anti-PD-1 therapy may enhance the anti-tumor activity of the combination due to the complementary nature of the two mechanisms Adcendo will sponsor the Phase 1b clinical trial and MSD will provide pembrolizumab COPENHAGEN, Denmark, May 26, 2026 /PRNewswire/ -- Adcendo ApS ("Adcendo"), a biotech company focused on the development of first- and best-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high u

LOS ANGELES--(BUSINESS WIRE)--BioTools Innovator (BTI), the first accelerator focused exclusively on life science tools and diagnostics startups, has selected 30 companies for its 2026 Accelerator program. These startups will participate in a four-month program offering in-depth, personalized mentorship from senior industry leaders, access to funding opportunities, and meaningful engagement with peers and expert advisors. Chosen from a highly competitive pool of nearly 550 applicants, the select

Lead program is a Phase 1-ready EBV vaccine candidate with potential to prevent infectious mononucleosis and the serious long-term conditions associated with EBV infection BETHESDA, Md., May 26, 2026 /PRNewswire/ -- Vaccine Company, Inc. (Vaccine Company), a privately held pre-clinical-stage biotechnology company developing next-generation vaccines for infectious diseases, today announced entry into a definitive agreement to be acquired by Lilly. Vaccine Company's proprietary In Vivo Nanopartic

Agreements with Curevo, LimmaTech Biologics and Vaccine Company address viral pathogens linked to long-term neurological and oncological risk, and bacterial pathogens that are difficult to prevent or treat Acquisitions build on Lilly's infectious disease legacy and reinforce its commitment to prevention strategies that reduce the long-term burden of serious disease INDIANAPOLIS, May 26, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced agreements to acquire three companies,

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, with a fireside chat at 10:00 a.m. EDT. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. An archived webcast will be available on the Company’s website. About BeOne BeOne Medi

SOUTH SAN FRANCISCO, Calif., May 26, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the following events at the 2026 Jefferies Global Healthcare Conference. 2026 Jefferies Global Healthcare Conference Wednesday, June 3rd, 2026 at 7:35 AM ET Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Maury Raycroft, Ph.D.

BOSTON, May 26, 2026 /PRNewswire/ -- ZETA SURGICAL today announced the first commercial deployment of its FDA-cleared Zeta TMS Navigation System. The system will be utilized at HOPE Therapeutics in West Palm Beach, Florida, to deliver high-precision navigated Transcranial Magnetic Stimulation (TMS) for the treatment of Major Depressive Disorder and other neurological conditions. Continue Reading Zeta Navigation System TMS is a non-invasive therapy primarily used for treatment-resistant depressio

DALLAS, May 26, 2026 /PRNewswire/ -- Koya Medical ("Koya"), an emerging medtech innovator advancing patient-centered solutions in vascular health, has announced its participation in the following investor conferences from June 2 to June 4, 2026: 2026 Jefferies Global Healthcare Conference in New York, holding private meetings on Tuesday, June 2, 2026 William Blair's 46th Annual Growth Stock Conference (PrivaTRAK) in Chicago, holding private meetings on Wednesday, June 3, 2026 Andy Doraiswamy (CE

NEW YORK, May 26, 2026 /PRNewswire/ -- AVANT BIO, the growth equity firm investing in life science industrials and enabling technologies, today announced the appointment of Maik W. Jornitz and Lukas Utiger as Operating Advisors. In their new roles, both advisors will work alongside AVANT BIO's portfolio companies to support operational scaling, business development, and strategic growth initiatives, including service on portfolio company boards. Continue Reading Lukas Utiger and Maik Jornitz The